menu
    • menu
    [{"orgOrder":0,"company":"XOMA","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Interleukin-2","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Zydus Cadila","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Zydus Cadila"},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"RZ358","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rezolute"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Gemcitabine Hydrochloride","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.52000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Novartis"},{"orgOrder":0,"company":"XOMA","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enzyme replacement therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"XOMA","amount2":0.14999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"XOMA \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Chiesi Group"},{"orgOrder":0,"company":"XOMA","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Mezagitamab","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"XOMA","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"XOMA \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Takeda"},{"orgOrder":0,"company":"XOMA","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Cetrelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Janssen Biotech","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Janssen Biotech"},{"orgOrder":0,"company":"XOMA","sponsor":"Kuros Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Nivolumab","moa":"TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"XOMA \/ XOMA Corporation","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ XOMA Corporation"},{"orgOrder":0,"company":"XOMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"TGF beta","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Not Applicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Gemcitabine","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.52000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis"},{"orgOrder":0,"company":"XOMA","sponsor":"ObsEva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Ebopiprant","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"XOMA","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"XOMA \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"AZP-40XX","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Amolyt Pharma","highestDevelopmentStatusID":"4","companyTruncated":"XOMA \/ Amolyt Pharma"},{"orgOrder":0,"company":"XOMA","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Coagulation Factor IX (recombinant)","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"XOMA","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"","sponsorNew":"XOMA \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"LadRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"AE-Keto-Sulf07","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"XOMA","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"XOMA \/ XOMA","highestDevelopmentStatusID":"5","companyTruncated":"XOMA \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Immediate-Release Tablet","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"XOMA","sponsor":"LadRx","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Arimoclomol","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"XOMA","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"XOMA \/ XOMA","highestDevelopmentStatusID":"9","companyTruncated":"XOMA \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Talphera","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"XOMA","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"XOMA \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Exarafenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ XOMA","highestDevelopmentStatusID":"6","companyTruncated":"XOMA \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Faricimab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"XOMA","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"XOMA \/ Blue Owl Capital","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ Blue Owl Capital"},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"XOMA","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Immediate-Release Tablet","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"XOMA","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Ferrous Gluconate","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"XOMA","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Ring","sponsorNew":"XOMA \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Viracta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"XOMA","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"XOMA \/ Viracta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ Viracta Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by XOMA

    Menu

    XOMA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Viracta Therapeutics

                            Deal Size : $108.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Receives $8.1 Million Milestone for Day One Biopharmaceuticals’ Priority Voucher

                            Details : XOMA acquired potential milestones associated with Ojemda (tovorafenib), approved for patients 6 months age and older with relapsed or refractory pediatric low-grade glioma with BRAF V600 mutation.

                            Brand Name : Ojemda

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Viracta Therapeutics

                            Deal Size : $108.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Recipient : Daré Bioscience

                            Deal Size : $22.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Dar© Secures $22M Royalty Financing for Women's Health Product Candidates

                            Details : Proceeds will advance Ovaprene, an intravaginal contraceptive ring, and Sildenafil Cream, a potential FDA-approved treatment for female sexual arousal disorder.

                            Brand Name : Ovaprene

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Recipient : Daré Bioscience

                            Deal Size : $22.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $54.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Earns $9 Million Milestone As FDA Approves OJEMDATM for pLGG

                            Details : XOMA acquired mid-single digit royalties related to Ojemda (tovorafenib), approved for treating patients aged 6 months and older with r/r pediatric low-grade glioma harboring BRAF V600 mutation.

                            Brand Name : Ojemda

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 25, 2024

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $54.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Kinnate Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kinnate Biopharma to Be Acquired By XOMA Corporation for Up to $2.5879 Per Share

                            Details : XOMA gains access to KIN-2787 (exarafenib), a potent and selective investigational small molecule pan-RAF inhibitor, being evaluated for BRAF/NRAS-mutated advanced or metastatic solid tumors.

                            Brand Name : KIN-2787

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2024

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Kinnate Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Talphera

                            Deal Size : $8.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

                            Details : XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.

                            Brand Name : Dsuvia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 18, 2024

                            Lead Product(s) : Sufentanil Citrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Talphera

                            Deal Size : $8.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arimoclomol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Recipient : LadRx

                            Deal Size : $58.6 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            FDA Accepts Zevra's Arimoclomol NDA for NPC Type C, Triggering Milestone Payment

                            Details : XOMA acquired royalty and milestone rights for LadRx Corporation’s BRX-345 (arimoclomol) for Niemann-Pick Disease Type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin.

                            Brand Name : BRX-345

                            Molecule Type : Small molecule

                            Upfront Cash : $5.0 million

                            January 11, 2024

                            Lead Product(s) : Arimoclomol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Recipient : LadRx

                            Deal Size : $58.6 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Faricimab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Blue Owl Capital

                            Deal Size : $140.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital ...

                            Details : Vabysmo (faricimab-svoa) is the first bispecific antibody which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising Ang-2 and VEGF-A. It is being investigated for the treatment of retin...

                            Brand Name : Vabysmo

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 19, 2023

                            Lead Product(s) : Faricimab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Blue Owl Capital

                            Deal Size : $140.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $59.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Earns $5 Million Milestone upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive P...

                            Details : Under the agreement, XOMA acquired potential royalty economics related to DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor, being developed as a monotherapy for relapsed or progressive pediatr...

                            Brand Name : DAY101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : Tovorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Day One Biopharmaceuticals

                            Deal Size : $59.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AE-Keto-Sulf07

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : LadRx

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

                            Details : The Company expects to use the proceeds to advance its lead novel LADR-based anti-cancer drug, LADR-7 (AE-keto-sulf07) towards an IND filing with the FDA.

                            Brand Name : LADR7

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 22, 2023

                            Lead Product(s) : AE-Keto-Sulf07

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : LadRx

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XOMA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coagulation Factor IX (recombinant)

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Aptevo Therapeutics

                            Deal Size : $9.6 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

                            Details : Through the aquisition, XOMA gains the milestone rights to IXINITY® [coagulation factor IX (recombinant)], which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Ap...

                            Brand Name : Ixinity

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Coagulation Factor IX (recombinant)

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Aptevo Therapeutics

                            Deal Size : $9.6 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth